To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients
Completed · Phase 2 · Has a placebo group
Conditions studied: Postoperative Pain
In brief
The study will assess the analgesic efficacy and safety and tolerability of a single oral dose of SAF312 in postoperative dental pain patients after 3rd molar extraction.
Key facts
- Study ID
- NCT00986882
- Run by
- Novartis
- People needed
- 183
- Starts
- 2009-09-01
- Expected to finish
- 2011-03-01
- Last updated by the study team
- 2020-12-19
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Extraction of two or more impacted (partial or full) third molars. At least one of the impaction should be lower jaw.
- Each patient will evaluate her/his post-surgical pain intensity prior to taking trial medication.
- To be eligible for this trial, post surgical pain must be moderate to severe -- Subjects should be in good health otherwise as determined by past medical history, physical examination, vital signs, electrocardiogram and laboratory tests at screening.
- Female subjects should be either postmenopausal or should have had surgical sterilization.
You may not qualify if…
- Patients with known hypersensitivity to diclofenac, aspirin, acetaminophen or to antipyretics or with allergies manifested by attacks of asthma, urticaria or acute rhinitis following treatment with aspirin or other agents with cyclooxygenase-inhibiting activity such as NSAIDs.
- Use of antipyretic/analgesic drugs from 48 hrs pre-dose to 24 hrs postdose
- Presence of bleeding disorder (history of excessive bleeding after dental procedures or minor injuries)
- Patients with Diabetes mellitus.
- Presence, history of, or family history of malignant hyperthermia or anesthesia-related events that may be suggestive of malignant hyperthermia.
- An abnormal ECG at screening, including PR>200 ms, QRS>110 ms, QTcF<380 or >450 ms, lead II T wave abnormalities. Non-specific T wave abnormalities in leads other than lead II are permissible if not accompanied by any other morphological abnormalities.
- Patients with infection e.g. dental abscess
- Other protocol-defined inclusion/exclusion criteria may apply
Where it is running
- Jean Brown Research — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.